Compare MSGM & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MSGM | INTS |
|---|---|---|
| Founded | 2018 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4M | 12.4M |
| IPO Year | 2020 | 2021 |
| Metric | MSGM | INTS |
|---|---|---|
| Price | $4.30 | $3.92 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $38.00 |
| AVG Volume (30 Days) | ★ 47.2K | 23.8K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 252.13 | N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $741,000.00 | N/A |
| Revenue This Year | $69.73 | N/A |
| Revenue Next Year | $146.81 | N/A |
| P/E Ratio | $72.67 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.11 | $0.19 |
| 52 Week High | $5.78 | $8.06 |
| Indicator | MSGM | INTS |
|---|---|---|
| Relative Strength Index (RSI) | 47.36 | 35.46 |
| Support Level | $3.95 | $0.31 |
| Resistance Level | $4.57 | $8.06 |
| Average True Range (ATR) | 0.22 | 0.23 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 63.64 | 36.83 |
Motorsport Games Inc is a motorsport network company that combines engaging video games with esports competitions and content for racing fans and gamers around the globe. The company has its reportable segments into the development and publishing of interactive racing video games, entertainment content and services, and the organization and facilitation of esports tournaments, competitions, and events for licensed racing games as well as on behalf of third-party video game racing series and other video game publishers. The majority of the revenue is earned from Gaming.
Intensity Therapeutics Inc . is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.